What's New

News

2015/11/10
Nippon Kayaku Announces License Agreement with Eiger BioPharmaceuticals to Develop BestatinTM (ubenimex) for Inflammatory Diseases Involving LTB4
2015/10/06
Updated information of CSR
2015/10/05
Maintenance notification
2015/07/30
Nippon Kayaku Announces Start-up Clinical Trial in Japan as the part of Global Phase 3 Clinical Trial Program for CT-P6 in Breast Cancer
2015/06/08
Management Changes (Appointments & Transfers)
2015/04/21
We have published CSR Procurement.
2015/03/31
Nippon Kayaku is pleased to announce that the English version of its corporate website has been revamped and an all new Chinese version has been published.
PageTop
Corporate Vision
Our Business
Corporate Information
Global Netowork
Investor Relations
CSR